Released Nov 12, 2026, before the open
10-Q filed Nov 12, 2026, 43 days after period end · 0001193125-26-458388
What the release said
On November 12, 2026, Parabilis Medicines, Inc. (the “Company”) announced its financial results and business highlights for the quarter ended September 30, 2026.
Parabilis Medicines reported a net loss of $44.5 million for the quarter ended September 30, 2026, compared to $33.5 million for the comparable prior-year period.¶2
Revenue was $2.1 million from collaboration agreements, research and development expenses were $45.6 million, and general and administrative expenses were $11.3 million for the quarter.¶3¶4¶5
Cash, cash equivalents and marketable securities were $1.1 billion as of September 30, 2026, which the company expects to fund operations into 2030.¶6¶7
The company reached alignment with the U.S. Food and Drug Administration on a global Phase 3 trial design and plans to initiate the PEDESTAL registrational trial in the first half of 2027.¶8¶9
- Net loss
- $44.5 million Quarter ended September 30, 2026, compared to $33.5 million for the comparable prior-year period¶2
- Revenue
- $2.1 million Quarter ended September 30, 2026, from collaboration agreements, compared to no revenue in the comparable prior-year period¶3
- Research and development expenses
- $45.6 million Quarter ended September 30, 2026, compared to $28.2 million for the comparable prior-year period¶4
- General and administrative expenses
- $11.3 million Quarter ended September 30, 2026, compared to $6.6 million for the comparable prior-year period¶5
- Cash, cash equivalents and marketable securities
- $1.1 billion As of September 30, 2026, compared to $27.7 million as of December 31, 2025¶7
Same quarter
| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | $2.11M | $0.00 |
| Net Income | -$44.49M | -$33.48M |
| EPS Diluted | -$0.36 | -$21.66 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Parabilis Medicines, Inc. · CIK 1657677 · Engraved from SEC EDGAR